This blog will cover tweets from the meeting dates March 21-22, 2016 .
The presentation by Dr Frey will be covered in a separate blog post.Frey: Ovarian cancer survivorship data-acceptance of toxicities change as goals of treatment change. #SGOmtg pic.twitter.com/4W1LGHjlSw— Annie Ellis (@Stigetta) March 21, 2016
You may find more information on enhanced recovery pathways in this journal article. (Enhanced Recovery in Gyneocologic Surgery http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913481/ )L. Meyer - enhanced recovery pathway in gyn onc surgery results in improved post op day 1 fatigue, nausea, and drowsiness! #gyncsm #SGOmtg— Shannon Westin (@ShannonWestin) March 21, 2016
Excellent distillation Lari Wenzel! Patients live longer AND better w/patient-centered outcomes research #SGOmtg pic.twitter.com/8nxpY67VWA— Annie Ellis (@Stigetta) March 21, 2016
A. Fader - small numbers but encouraging activity of pembrolizumab in recurrent #endometrial cancer https://t.co/csqF6hHRHi #gyncsm #SGOmtg— Shannon Westin (@ShannonWestin) March 21, 2016
#SGOmtg Dr Matulonis on Cabozantinib vs Weekly Packitaxel in recurrent #Ovariancancer no improvement in OS— BJ Rimel (@BJRimelMD) March 21, 2016
PFS similar between all arms of GOG252 - dose dense vs IP with Cisplatin vs IP with Carboplatin. Now - to evaluate QOL! #gyncsm #SGOMtg— Shannon Westin (@ShannonWestin) March 21, 2016
GOG 252 results at #sgomtg put into question the benefit of IP chemotherapy in newly dxed #ovariancancer pts— Ursula Matulonis, MD (@DrMatulonis) March 21, 2016
@womenofteal The presentation after results was on QOL and PROs, which totally did not favor IP cis. And without a PFS benefit, it's tough.— Erin Stevens (@erinstevensmd) March 22, 2016
Ovarian cancer surgery with a general surgeon increases the risk of ostomy without clear clinical benefit #SGOmtg pic.twitter.com/0PCtq3podc— Leslie Clark (@lesliehclark) March 22, 2016
Thank you to all the researchers who consider the needs of their patients as they develop better treatments, detection tests and a cure.BRCA mutations are linked to a longer survival in patients with ovarian cancer, study shows https://t.co/Ws5vv4jgCm #SGOmtg— OncLive.com (@OncLive) March 21, 2016
Every Day is a Blessing!